James E. Flynn - 06 Feb 2024 Form 4 Insider Report for Fractyl Health, Inc. (GUTS)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
08 Feb 2024, 14:07:12 UTC
Prior SEC filing
01 Feb 2024
Next SEC filing
16 Feb 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jonathan Isler, Attorney-in-Fact

Key filing fact

James E. Flynn filed Form 4 for Fractyl Health, Inc. (GUTS) on 08 Feb 2024.

Key facts

  • This page summarizes James E. Flynn's Form 4 filing for Fractyl Health, Inc. (GUTS).
  • 4 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 08 Feb 2024, 14:07.

Change

  • Previous filing in this sequence was filed on 01 Feb 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GUTS transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+757,548
Change %
Price
Shares after
757,548
Date
06 Feb 2024
Ownership
Through Deerfield Private Design Fund III, L.P.
Footnotes
F1, F2, F3
GUTS transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+76,706
Change %
+10%
Price
Shares after
834,254
Date
06 Feb 2024
Ownership
Through Deerfield Private Design Fund III, L.P.
Footnotes
F2, F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GUTS transaction Derivative

Series C-2 Preferred Stock

Conversion of derivative security

Transaction value
Shares
-1,625,699
Change %
-100%
Price
Shares after
0
Date
06 Feb 2024
Ownership
Through Deerfield Private Design Fund III, L.P.
Underlying class
Common Stock
Underlying amount
757,548
Exercise price
Footnotes
F1, F2, F3
GUTS transaction Derivative

Series D Preferred Stock

Conversion of derivative security

Transaction value
Shares
-164,612
Change %
-100%
Price
Shares after
0
Date
06 Feb 2024
Ownership
Through Deerfield Private Design Fund III, L.P.
Underlying class
Common Stock
Underlying amount
76,706
Exercise price
Footnotes
F2, F3, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

James E. Flynn is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

Each share of Series C-2 Preferred Stock automatically converted into 0.46598 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering (on an adjusted basis after giving effect to the 1-for-2.146 reverse split of the Issuer's common stock effected by the Issuer on January 26, 2024).

Footnote F2

This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. (the "Fund"). Deerfield Management Company, L.P. is the investment manager of the Fund. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P. and Deerfield Management Company, L.P.

Footnote F3

In accordance with Instruction 4(b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Fund is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Footnote F4

Each share of Series D Preferred Stock automatically converted into 0.46598 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering (on an adjusted basis after giving effect to the 1-for-2.146 reverse split of the Issuer's common stock effected by the Issuer on January 26, 2024).

SEC remarks

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 4 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on August 3, 2021 by Deerfield Partners, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and James E. Flynn

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .